查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951789

氣喘生物製藥市場分析及預測（至2035年）：依類型、產品、應用、最終用戶、技術、設備、階段、成分、實施類型及解決方案分類

Asthma Biologics Market Analysis and Forecast to 2035: Type, Product, Application, End User, Technology, Device, Stage, Component, Deployment, Solutions
出版日期: | 出版商: Global Insight Services | 英文 348 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計氣喘生物製藥市場將從2024年的74億美元成長到2034年的235億美元，複合年成長率約為12.3%。氣喘生物製藥市場涵蓋了透過調節特定免疫路徑來治療重度氣喘的先進療法。這些生物製藥產品（通常是單株抗體）提供個人化治療方案，可減少氣喘發作頻率並提高患者的生活品質。氣喘盛行率上升、生物技術進步和醫療保健支出增加是推動市場成長的主要因素。新型生物製藥的研發、策略合作和適應症的拓展等關鍵趨勢預計將推動市場強勁成長。

由於氣喘盛行率不斷上升以及對先進治療方法的需求日益成長，氣喘生物製藥市場正經歷顯著成長。單株抗體細分市場是成長最快的子細分市場，這得益於其能夠有效靶向氣喘相關的特定路徑。尤其值得關注的是抗IgE和抗IL-5生物製藥，它們能夠為重度氣喘患者提供標靶症狀緩解。白細胞介素抑制劑細分市場也緊隨其後，這反映出其良好的臨床療效使其應用日益廣泛。針對特定細胞激素和受體的創新治療方法正在蓬勃發展，為患者提供個人化的治療方案。研發活動也集中在開發具有更高療效和安全性的新型生物製藥。先進診斷工具的整合能夠達到精準的患者分層，進而最佳化治療效果。此外，製藥公司之間的策略聯盟和夥伴關係正在推動創新並加速市場滲透。隨著醫療基礎設施的改善和患者意識的提高，預計氣喘治療領域對生物製藥的需求將會增加。

市場區隔
類型 單株抗體、白細胞介素抑制劑、抗IgE、抗IL-5、抗IL-4
產品 吸入器、注射、口服錠、霧化器
目的 重度氣喘、中度氣喘、兒童氣喘、成人氣喘
最終用戶 醫院、診所、居家醫療、研究機構、製藥公司
科技 生物技術、基因組學和蛋白​​質組學
裝置 攜帶式設備、固定式設備、穿戴式裝置
步 臨床試驗、商業化與在研發線產品
成分 活性成分、添加物、穩定劑
實施表格 本機部署、雲端部署
解決方案 患者管理、藥物輸送系統

氣喘生物製藥市場的特徵是市場佔有率、定價策略和產品創新之間存在著動態的相互作用。現有企業利用其廣泛的產品系列和策略性定價策略來維持競爭優勢並主導市場。然而，新參與企業正以創新的生物製藥療法為市場注入新的活力，進一步加劇了競爭格局。定價仍然是關鍵因素，受到生產複雜性和監管路徑的影響。近期推出的產品凸顯了該行業為滿足未被滿足的需求、提高治療效果和改善患者預後所做的努力。競爭基準分析顯示，主要市場參與企業之間的競爭異常激烈，每家企業都在追求技術優勢和市場滲透率。監管影響，尤其是在北美和歐洲，對市場准入和合規標準起著至關重要的作用。專利到期和生物相似藥的推出加劇了競爭，並進一步塑造了市場格局。分析結果表明，隨著企業尋求鞏固其市場地位，策略聯盟和收購十分普遍。在個人化醫療的進步和全球氣喘盛行率不斷上升的推動下，該市場的成長前景十分樂觀。

主要趨勢和促進因素：

受個人化醫療的進步和全球氣喘患者數量不斷成長的推動，氣喘生物製藥市場正經歷強勁成長。關鍵趨勢包括生物製藥與數位健康技術的融合，有助於改善患者管理並提高治療依從性。單株抗體作為首選治療方案的出現，推動了市場向標靶治療的轉變，有助於改善患者預後並減少病情惡化。推動該市場發展的因素包括氣喘認知度和診斷率的提高，以及醫療費用支出的顯著成長。未被滿足的醫療需求和傳統氣喘治療方法的限制進一步推動了對創新治療方法的需求。此外，監管部門對生物製藥的支持和加速核准流程正在加速其市場准入和應用。新興市場蘊藏大量機遇，這些市場的醫療基礎設施不斷完善，生物製藥的可近性也不斷擴大。專注於開發經濟高效且易於獲取的治療方法的公司，將佔據有利地位，從而獲得可觀的市場佔有率。此外，生物技術公司與醫療保健機構之間的合作正在促進創新，並擴大氣喘生物製藥的覆蓋範圍。在技​​術進步和對以患者為中心的護理日益重視的推動下，市場預計將持續成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 單株抗體
    • 白細胞介素抑制劑
    • 抗IgE
    • 抗IL-5
    • 抗IL-4
  • 市場規模及預測：依產品分類
    • 吸入器
    • 注射
    • 口服錠劑
    • 噴霧器
  • 市場規模及預測：依應用領域分類
    • 重度氣喘
    • 中度氣喘
    • 兒童氣喘
    • 成人氣喘
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 居家醫療
    • 研究所
    • 製藥公司
  • 市場規模及預測：依技術分類
    • 生物技術
    • 基因組學
    • 蛋白質體學
  • 市場規模及預測：依設備分類
    • 攜帶式裝置
    • 固定設備
    • 穿戴式裝置
  • 市場規模及預測：依階段分類
    • 臨床試驗
    • 商業化
    • 研發線產品
  • 市場規模/預測：依成分分類
    • 活性成分
    • 添加劑
    • 穩定器
  • 市場規模及預測：依實施類型分類
    • 本地部署
    • 基於雲端的
  • 市場規模及預測：按解決方案分類
    • 病患管理
    • 藥物輸送系統

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Circassia Pharmaceuticals
  • Aimmune Therapeutics
  • DBV Technologies
  • Allakos
  • Kymab
  • Astra Zeneca
  • Amgen
  • Teva Pharmaceutical Industries
  • GSK
  • Regeneron Pharmaceuticals
  • Sanofi
  • Novartis
  • Chiesi Farmaceutici
  • ALK-Abello
  • Mabtech
  • Genentech
  • Boehringer Ingelheim
  • Biogen
  • Alkermes
  • Innovent Biologics

第9章：關於我們

簡介目錄
Product Code: GIS26164

Asthma Biologics Market is anticipated to expand from $7.4 billion in 2024 to $23.5 billion by 2034, growing at a CAGR of approximately 12.3%. The Asthma Biologics Market encompasses advanced therapeutic solutions targeting severe asthma by modulating specific immune pathways. These biologics, often monoclonal antibodies, offer personalized treatment options, reducing exacerbations and improving patient quality of life. The market is driven by rising asthma prevalence, advancements in biotechnology, and increased healthcare expenditure. Key trends include the development of novel biologics, strategic collaborations, and expanding indications, positioning the market for robust growth.

The Asthma Biologics Market is experiencing significant growth, driven by the rising prevalence of asthma and the need for advanced treatment options. The monoclonal antibodies segment is the top-performing sub-segment, owing to its effectiveness in targeting specific pathways involved in asthma. Anti-IgE and anti-IL-5 biologics are particularly noteworthy, as they offer targeted relief for severe asthma patients. The interleukin inhibitors segment follows closely, reflecting their growing adoption due to promising clinical outcomes. Innovative therapies targeting specific cytokines and receptors are gaining momentum, offering personalized treatment approaches. The market is also witnessing increased research and development activities focused on novel biologics, enhancing treatment efficacy and safety profiles. The integration of advanced diagnostic tools is facilitating precise patient stratification, optimizing therapeutic outcomes. Moreover, strategic collaborations and partnerships among pharmaceutical companies are fostering innovation and accelerating market penetration. The demand for biologics in asthma management is set to rise, driven by improved healthcare infrastructure and patient awareness.

Market Segmentation
TypeMonoclonal Antibodies, Interleukin Inhibitors, Anti-IgE, Anti-IL-5, Anti-IL-4
ProductInhalers, Injectables, Oral Tablets, Nebulizers
ApplicationSevere Asthma, Moderate Asthma, Pediatric Asthma, Adult Asthma
End UserHospitals, Clinics, Homecare Settings, Research Institutes, Pharmaceutical Companies
TechnologyBiotechnology, Genomics, Proteomics
DevicePortable Devices, Stationary Devices, Wearable Devices
StageClinical Trials, Commercialized, Pipeline Products
ComponentActive Ingredients, Excipients, Stabilizers
DeploymentOn-premise, Cloud-based
SolutionsPatient Management, Drug Delivery Systems

The Asthma Biologics Market is characterized by a dynamic interplay of market share, pricing strategies, and product innovations. Established players dominate, leveraging their extensive portfolios and strategic pricing to maintain competitive advantage. New entrants, however, are invigorating the market with novel biologic therapies, fostering a competitive landscape. Pricing remains a pivotal factor, influenced by manufacturing complexities and regulatory pathways. Recent product launches underscore the industry's commitment to addressing unmet clinical needs, offering enhanced therapeutic efficacy and patient outcomes. Competition benchmarking reveals a robust rivalry among key market participants, with each striving for technological superiority and market penetration. Regulatory influences, particularly in North America and Europe, are pivotal, dictating market entry and compliance standards. The landscape is further shaped by patent expirations and biosimilar introductions, intensifying competition. Analytical insights indicate that strategic alliances and acquisitions are prevalent, as companies seek to bolster their market positions. The market trajectory is promising, driven by advancements in personalized medicine and increasing prevalence of asthma globally.

Geographical Overview:

The Asthma Biologics Market is experiencing notable expansion across various regions, each exhibiting unique growth dynamics. North America remains at the forefront, driven by advanced healthcare infrastructure and high prevalence of asthma. The region's strong focus on research and development fosters innovation in biologic therapies, enhancing market growth. Europe follows closely, with significant investments in healthcare and a rising demand for advanced asthma treatments. The region's emphasis on improving patient outcomes and quality of life further propels the market. In Asia Pacific, the market is expanding rapidly, supported by increasing asthma prevalence and growing healthcare expenditure. Emerging economies such as China and India are witnessing substantial growth, attributed to improving healthcare access and rising awareness of biologic treatments. Latin America and the Middle East & Africa present emerging growth pockets. These regions are increasingly recognizing the potential of biologics in addressing asthma, driving investments and fostering market development.

Global tariffs and geopolitical tensions are significantly influencing the Asthma Biologics Market, particularly in East Asia. In Japan and South Korea, the focus is on bolstering domestic production capabilities to mitigate reliance on foreign biologics, spurred by potential tariff escalations. China's strategy includes enhancing its biopharmaceutical sector through substantial investment in R&D and fostering local innovation, a response to both trade restrictions and the need for self-sufficiency. Taiwan, while a pivotal player in biologics manufacturing, faces geopolitical vulnerabilities due to its proximity to China. Globally, the asthma biologics sector is experiencing robust growth, driven by rising asthma prevalence and innovation in biologic therapies. By 2035, the market is expected to thrive on strategic regional collaborations and resilient supply chains, despite potential disruptions from Middle East conflicts affecting energy prices and logistics.

Key Trends and Drivers:

The Asthma Biologics Market is experiencing robust growth, driven by advancements in personalized medicine and increased prevalence of asthma worldwide. Key trends include the integration of biologics with digital health technologies, facilitating better patient management and adherence to treatment regimens. The rise of monoclonal antibodies as a preferred treatment option underscores the market's shift towards targeted therapies, enhancing patient outcomes and reducing exacerbations. Drivers of this market include the growing awareness and diagnosis rates of asthma, coupled with a significant rise in healthcare expenditure. The demand for innovative therapies is further propelled by unmet medical needs and the limitations of traditional asthma treatments. Additionally, regulatory support and expedited approval processes for biologics are accelerating market entry and adoption. Opportunities are abundant in emerging markets where healthcare infrastructure is improving, and access to biologics is expanding. Companies that focus on developing cost-effective and accessible treatment options are well-positioned to capture significant market share. Furthermore, partnerships and collaborations between biotech firms and healthcare providers are fostering innovation and expanding the reach of asthma biologics. The market is poised for sustained growth, driven by technological advancements and an increasing focus on patient-centric care.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by End User
  • 2.5 Key Market Highlights by Technology
  • 2.6 Key Market Highlights by Device
  • 2.7 Key Market Highlights by Stage
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Interleukin Inhibitors
    • 4.1.3 Anti-IgE
    • 4.1.4 Anti-IL-5
    • 4.1.5 Anti-IL-4
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Inhalers
    • 4.2.2 Injectables
    • 4.2.3 Oral Tablets
    • 4.2.4 Nebulizers
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Severe Asthma
    • 4.3.2 Moderate Asthma
    • 4.3.3 Pediatric Asthma
    • 4.3.4 Adult Asthma
  • 4.4 Market Size & Forecast by End User (2020-2035)
    • 4.4.1 Hospitals
    • 4.4.2 Clinics
    • 4.4.3 Homecare Settings
    • 4.4.4 Research Institutes
    • 4.4.5 Pharmaceutical Companies
  • 4.5 Market Size & Forecast by Technology (2020-2035)
    • 4.5.1 Biotechnology
    • 4.5.2 Genomics
    • 4.5.3 Proteomics
  • 4.6 Market Size & Forecast by Device (2020-2035)
    • 4.6.1 Portable Devices
    • 4.6.2 Stationary Devices
    • 4.6.3 Wearable Devices
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Clinical Trials
    • 4.7.2 Commercialized
    • 4.7.3 Pipeline Products
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Active Ingredients
    • 4.8.2 Excipients
    • 4.8.3 Stabilizers
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 On-premise
    • 4.9.2 Cloud-based
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Patient Management
    • 4.10.2 Drug Delivery Systems

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 End User
      • 5.2.1.5 Technology
      • 5.2.1.6 Device
      • 5.2.1.7 Stage
      • 5.2.1.8 Component
      • 5.2.1.9 Deployment
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 End User
      • 5.2.2.5 Technology
      • 5.2.2.6 Device
      • 5.2.2.7 Stage
      • 5.2.2.8 Component
      • 5.2.2.9 Deployment
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 End User
      • 5.2.3.5 Technology
      • 5.2.3.6 Device
      • 5.2.3.7 Stage
      • 5.2.3.8 Component
      • 5.2.3.9 Deployment
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 End User
      • 5.3.1.5 Technology
      • 5.3.1.6 Device
      • 5.3.1.7 Stage
      • 5.3.1.8 Component
      • 5.3.1.9 Deployment
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 End User
      • 5.3.2.5 Technology
      • 5.3.2.6 Device
      • 5.3.2.7 Stage
      • 5.3.2.8 Component
      • 5.3.2.9 Deployment
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 End User
      • 5.3.3.5 Technology
      • 5.3.3.6 Device
      • 5.3.3.7 Stage
      • 5.3.3.8 Component
      • 5.3.3.9 Deployment
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 End User
      • 5.4.1.5 Technology
      • 5.4.1.6 Device
      • 5.4.1.7 Stage
      • 5.4.1.8 Component
      • 5.4.1.9 Deployment
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 End User
      • 5.4.2.5 Technology
      • 5.4.2.6 Device
      • 5.4.2.7 Stage
      • 5.4.2.8 Component
      • 5.4.2.9 Deployment
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 End User
      • 5.4.3.5 Technology
      • 5.4.3.6 Device
      • 5.4.3.7 Stage
      • 5.4.3.8 Component
      • 5.4.3.9 Deployment
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 End User
      • 5.4.4.5 Technology
      • 5.4.4.6 Device
      • 5.4.4.7 Stage
      • 5.4.4.8 Component
      • 5.4.4.9 Deployment
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 End User
      • 5.4.5.5 Technology
      • 5.4.5.6 Device
      • 5.4.5.7 Stage
      • 5.4.5.8 Component
      • 5.4.5.9 Deployment
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 End User
      • 5.4.6.5 Technology
      • 5.4.6.6 Device
      • 5.4.6.7 Stage
      • 5.4.6.8 Component
      • 5.4.6.9 Deployment
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 End User
      • 5.4.7.5 Technology
      • 5.4.7.6 Device
      • 5.4.7.7 Stage
      • 5.4.7.8 Component
      • 5.4.7.9 Deployment
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 End User
      • 5.5.1.5 Technology
      • 5.5.1.6 Device
      • 5.5.1.7 Stage
      • 5.5.1.8 Component
      • 5.5.1.9 Deployment
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 End User
      • 5.5.2.5 Technology
      • 5.5.2.6 Device
      • 5.5.2.7 Stage
      • 5.5.2.8 Component
      • 5.5.2.9 Deployment
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 End User
      • 5.5.3.5 Technology
      • 5.5.3.6 Device
      • 5.5.3.7 Stage
      • 5.5.3.8 Component
      • 5.5.3.9 Deployment
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 End User
      • 5.5.4.5 Technology
      • 5.5.4.6 Device
      • 5.5.4.7 Stage
      • 5.5.4.8 Component
      • 5.5.4.9 Deployment
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 End User
      • 5.5.5.5 Technology
      • 5.5.5.6 Device
      • 5.5.5.7 Stage
      • 5.5.5.8 Component
      • 5.5.5.9 Deployment
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 End User
      • 5.5.6.5 Technology
      • 5.5.6.6 Device
      • 5.5.6.7 Stage
      • 5.5.6.8 Component
      • 5.5.6.9 Deployment
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 End User
      • 5.6.1.5 Technology
      • 5.6.1.6 Device
      • 5.6.1.7 Stage
      • 5.6.1.8 Component
      • 5.6.1.9 Deployment
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 End User
      • 5.6.2.5 Technology
      • 5.6.2.6 Device
      • 5.6.2.7 Stage
      • 5.6.2.8 Component
      • 5.6.2.9 Deployment
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 End User
      • 5.6.3.5 Technology
      • 5.6.3.6 Device
      • 5.6.3.7 Stage
      • 5.6.3.8 Component
      • 5.6.3.9 Deployment
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 End User
      • 5.6.4.5 Technology
      • 5.6.4.6 Device
      • 5.6.4.7 Stage
      • 5.6.4.8 Component
      • 5.6.4.9 Deployment
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 End User
      • 5.6.5.5 Technology
      • 5.6.5.6 Device
      • 5.6.5.7 Stage
      • 5.6.5.8 Component
      • 5.6.5.9 Deployment
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Circassia Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Aimmune Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 DBV Technologies
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Allakos
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Kymab
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Astra Zeneca
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Amgen
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Teva Pharmaceutical Industries
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 GSK
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Regeneron Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sanofi
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Novartis
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Chiesi Farmaceutici
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 ALK- Abello
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Mabtech
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Genentech
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Boehringer Ingelheim
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Biogen
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Alkermes
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Innovent Biologics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us